Barclays Reiterates an 'Overweight' Rating on Onyx Pharmaceuticals (ONXX); Broadening Support for CFZ at ASH
Tweet Send to a Friend
Barclays reiterates an 'Overweight' rating on Onyx Pharmaceuticals (NASDAQ: ONXX), raises PT from $35 to $42.
Barclays analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
